Population analyses of atorvastatin clearance in patients living in the community and in nursing homes

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 5, 2009, Pages 497-502

  Schwartz, J B ^a,b,c   Verotta, D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CYTOCHROME P450 3A;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; COMMUNITY; DEMOGRAPHY; DRUG CLEARANCE; FEMALE; HUMAN; MALE; MORNING DOSAGE; NURSING HOME; POPULATION; POPULATION RESEARCH; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP3A; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NURSING HOMES; PYRROLES; RESIDENCE CHARACTERISTICS; SEX FACTORS;

EID: 70350228243     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.100     Document Type: Article

References (23)

1. Lennernas, H. Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet. 42, 1141-1160 (2003).
2. Flockhart, D. Drug interactions. (cited 12 December 2007)
3. Gries, J.M., Benowitz, N. & Verotta, D. Chronopharmacokinetics of nicotine. Clin. Pharmacol. Ther. 60, 385-395 (1996).
4. Cilla, D.D., Gibson, D.M., Whitfeld, L.R. & Sedman, A.J. Pharmacodynamic efects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J. Clin. Pharmacol. 36, 604-609 (1996).
5. Jacobsen, W. et al. Lactonization is the critical frst step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab. Dispos. 28, 1369-1378 (2000).
6. Wilkinson, G.R. Drug metabolism and variability among patients in drug response. N. Engl. J. Med. 352, 2211-2221 (2005).
7. McLean, A.J. & Le Couteur, D.G. Aging biology and geriatric clinical pharmacology. Pharmacol. Rev. 56, 163-184 (2004).
8. Bressler, R. & Bahl, J.J. Principles of drug therapy for the elderly patient. Mayo Clin. Proc. 78, 1564-1577 (2003).
9. Cotreau, M.M., von Moltke, L.L. & Greenblatt, D.J. The infuence of age and sex on the clearance of cytochrome P450 3A substrates. Clin. Pharmacokinet. 44, 33-60 (2005).
10. Greenblatt, D.J., Abernethy, D.R., Locniskar, A., Harmatz, J.S., Limjuco, R.A. & Shader, R.I. Efect of age, gender, and obesity on midazolam kinetics. Anesthesiology 61, 27-35 (1984).
11. Greenblatt, D.J., Harmatz, J.S., von Moltke, L.L., Wright, C.E. & Shader, R.I. Age and gender efects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin. Pharmacol. Ther. 76, 467-479 (2004).
12. Greenblatt, D.J., Sellers, E.M. & Shader, R.I. Drug therapy: drug disposition in old age. N. Engl. J. Med. 306, 1081-1088 (1982).
13. Greenblatt, D.J., Shader, R.I. & Harmatz, J.S. Implications of altered drug disposition in the elderly: studies of benzodiazepines. J. Clin. Pharmacol. 29, 866-872 (1989).
14. Olubodun, J.O. et al. Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. Br. J. Clin. Pharmacol. 56, 297-304 (2003).
15. Krecic-Shepard, M.E., Park, K., Barnas, C., Slimko, J., Kerwin, D.R. & Schwartz, J.B. Race and sex infuence clearance of nifedipine: results of a population study. Clin. Pharmacol. Ther. 68, 130-142 (2000).
16. Kang, D., Verotta, D., Krecic-Shepard, M.E., Modi, N.B., Gupta, S.K. & Schwartz, J.B. Population analyses of sustained-release verapamil in patients: efects of sex, race, and smoking. Clin. Pharmacol. Ther. 73, 31-40 (2003).
17. Kang, D., Verotta, D. & Schwartz, J.B. Population analyses of amlodipine in patients living in the community and patients living in nursing homes. Clin. Pharmacol. Ther. 79, 114-124 (2006).
18. Lau, Y.Y., Huang, Y., Frassetto, L. & Benet, L.Z. Efect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin. Pharmacol. Ther. 81, 194-204 (2007).
19. Schwartz, J.B. Efects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. Clin. Pharmacol. Ther. 85, 198-203 (2009).
20. Block, G., Hartman, A.M., Dresser, C.M., Carroll, M.D., Gannon, J. & Gardner, L. A data-based approach to diet questionnaire design and testing. Am. J. Epidemiol. 124, 453-469 (1986).
21. Block, G., Hartman, A.M. & Naughton, D. A reduced dietary questionnaire: development and validation. Epidemiology 1, 58-64 (1990)
22. Beal, S. & Sheiner, L.B. NONMEM Users Guide. NONMEM Project Group. (University of California, San Francisco, 1991).
23. Wählby, U., Jonsson, E.N. & Karlsson, M.O. Assessment of actual signifcance levels for covariate efects in NONMEM. J. Pharmacokinet. Pharmacodyn. 28, 231-252 (2001).